Press release
Hemophilia A Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies and Companies by DelveInsight | Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, etc
Hemophilia A Pipeline
(Albany, USA) DelveInsight's 'Hemophilia A Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Hemophilia A therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hemophilia A pipeline domain.
For Hemophilia A emerging drugs, the Hemophilia A pipeline analysis report provides a 360 degrees view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
To know more in detail about Hemophilia A pipeline report, click here: [https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Hemophilia A Pipeline Report
* Over 40+ Hemophilia A pipeline therapies are in various stages of development, and their anticipated acceptance in the Hemophilia A market would significantly increase market revenue.
* Leading Hemophilia A companies developing novel drug candidates to improve the Hemophilia A treatment landscape include Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology, and others.
* Promising Hemophilia A pipeline therapies in various stages of development include SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Advate, Recombinate, antihemophilic factor, Eloctate, Hemlibra, Cyklokapron, NovoSeven RT, Xyntha, Humate-P, Hemofil-M, Adynovate, Afstyla, Feiba VH, Kogenate FS, Alphanate, Helixate FS, Autoplex T, Jivi, Nuwiq, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, and others.
* In June of 2023, BioMarin disclosed that the FDA had granted approval to Roctavian for use as a single-dose therapy in individuals with severe hemophilia A.
* In February 2023, the FDA in the United States gave the green light to ALTUVIIIO (efanesoctocog alfa), a replacement therapy for factor VIII, for both adults and children diagnosed with hemophilia A. ALTUVIIIO is prescribed for regular preventive measures, as well as for addressing bleeding incidents when needed, and for managing the perioperative period (surgery) in adults and children suffering from hemophilia A.
Request a sample and discover the recent breakthroughs happening Hemophilia A pipeline landscape: [https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hemophilia A Overview
Hemophilia is an inherited rare bleeding disorder in which blood does not clot properly because the affected person does not produce enough blood-clotting proteins (clotting factors). Patients who are injured cannot stop bleeding unless these factors are present. The severity of hemophilia symptoms is determined by the level of clotting factors. If the clotting factor level is mildly reduced, the patient may only bleed after surgery or trauma. If the deficiency is severe, one can easily bleed for no apparent reason. Small cuts are not dangerous, but internal bleeding is extremely dangerous for Hemophilia patients. Internal bleeding in the elbows, knees, ankles and other joints is the main concern with this genetic disorder. Internal bleeding can cause organ and tissue damage as well as be potentially fatal.
Hemophilia is classified into several types, including Hemophilia A, Hemophilia B, Hemophilia C, and Von Willebrand disease. Hemophilia is classified based on the presence of clotting factors, such as factor VIII in Hemophilia A and factor IX in Hemophilia B. Screening tests for hemophilia include the Complete Blood Count (CBC), Activated Partial Thromboplastin Time (APTT) Test, Prothrombin Time (PT) Test, Fibrinogen Test, and clotting factor tests.
Hemophilia A Pipeline Therapies and Key Companies
* Efanesoctocog alfa: Sanofi
* FRSW 107: Jiangsu Gensciences
* Mim8: Novo Nordisk
* SPK-8016: Spark Therapeutics
* OCTA101: Octapharma
* FRSW 117: Jiangsu Gensciences
* TQG203: Chia Tai Tianqing/Pharmaceutical Group
* STSP 0601: Staidson Beijing/BioPharmaceuticals
* P-FVIII-101: Poseida Therapeutics
Learn more about the Hemophilia A emerging pipeline therapies @ Hemophilia A Clinical Trials advancements: [https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hemophilia A Pipeline Therapeutics Assessment
By Product Type
* Monotherapy
* Combination Therapy
By Stage
* Discovery
* Pre-Clinical
* Phase I
* Phase II
* Phase III
* Pre-registration
By Route of Administration
* Oral
* Intravenous
* Subcutaneous
By Molecule Type
* Small molecules
* Gene Therapies
* Bispecific antibodies
* Recombinant proteins
* Fusion Proteins
* Coagulants
* Blood coagulation factor replacements
Request a sample and discover the recent breakthroughs happening Hemophilia A pipeline landscape: [https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Hemophilia A Pipeline Report
* Coverage: Global
* Key Hemophilia A Companies: Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology, and others.
* Key Hemophilia A Pipeline Therapies: SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, Advate, Recombinate, antihemophilic factor, Eloctate, Hemlibra, Cyklokapron, NovoSeven RT, Xyntha, Humate-P, Hemofil-M, Adynovate, Afstyla, Feiba VH, Kogenate FS, Alphanate, Helixate FS, Autoplex T, Jivi, Nuwiq and others.
Dive deep into rich insights for Hemophilia A emerging therapies and assessment; visit @ Hemophilia A Therapeutic Assessment: [https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Introduction
2. Executive Summary
3. Hemophilia A Overview
4. Hemophilia A Pipeline Therapeutics
5. Late Stage Products (Phase III)
6. Mid Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Hemophilia A Therapeutic Assessment
11. Inactive Hemophilia A Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Hemophilia A Unmet Needs
14. Hemophilia A Market Drivers and Barriers
15. Appendix
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-a-pipeline-assessment-2024-clinical-trials-fda-approvals-therapies-and-companies-by-delveinsight-spark-therapeutics-sigilon-therapeutics-asc-therapeutics-pfizer-sanofi-genzyme-etc]
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia A Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies and Companies by DelveInsight | Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, etc here
News-ID: 3465775 • Views: …
More Releases from ABNewswire
Arizona Balloon Company Releases 2025 Buyer's Guide to Advertising Blimps
Arizona Balloons Registered has released its 2025 Buyer's Guide to Advertising Blimps, a practical resource for marketing managers and procurement teams evaluating materials, safety practices, and total cost of ownership. The guide outlines key decision points-polyurethane vs. PVC, size selection for different sites, helium and staffing considerations, wind thresholds, and warranty terms-so buyers can compare vendors on more than just upfront price. For organizations planning to buy advertising blimps.
Why a…
Thoughts & Healing Prayers for Recovery from Addiction: How to Know God Intimate …
Award-winning authorMelissa A. Phoenix chronicles her descent into darkness and her subsequent recovery and redemption by releasing her book, Thoughts & Healing Prayers for Recovery from Addiction: How to Know God Intimately [https://www.amazon.ca/dp/1772776084].
Melissa is blunt, transparent, and doesn't ask for your understanding. Instead, she describes her experience and explains her thoughts and conclusions while offering you the chance to adapt and apply what has worked for her to your own…
HighJoule Releases 2025 Guide on How Many Solar Panels Needed to Power a House
Image: https://www.abnewswire.com/upload/2025/08/97bba235dc34dfb2a68dd164b66576ec.jpg
Introduction
2025, like, every year, is witness o an increasing demand for clean energy. Today the question in many homeowners' mouths is how many solar panels is necessary to power a house in today's world? The question doesn't have a single answer, because energy consumption will vary by house size, family lifestyle and type of solar panels installed. Changing technology For example, in 2025, panels are a lot more efficient,…
The Core Collab Launches the Sculptformer as a Megaformer Alternative
The boutique fitness brand introduces a high-performance machine that rivals elite reformers at a more accessible price point.
Image: https://www.abnewswire.com/upload/2025/08/3000f40b17c64921f46b6e108dda7b7c.jpg
California, United States - August 29, 2025 - The Core Collab, a boutique fitness brand with studios in both the United States and Australia, is reshaping the conversation around high-intensity Pilates with its latest innovation: the Sculptformer. Designed to rival the Megaformer and other elite training machines, the Sculptformer delivers the same…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
